A Polymorphism in MAPKAPK3 Affects Response to Interferon Therapy for Chronic Hepatitis C

Gastroenterology 136 巻 5 号 1796-1805 頁 2009 発行
アクセス数 : 961
ダウンロード数 : 248

今月のアクセス数 : 0
今月のダウンロード数 : 2
ファイル情報(添付)
Gastroenterology_136_1796.pdf 236 KB 種類 : 全文
タイトル ( eng )
A Polymorphism in MAPKAPK3 Affects Response to Interferon Therapy for Chronic Hepatitis C
作成者
Tsukada Hironobu
Maekawa Toshiro
Fujimoto Yoshifumi
Takahash Hiroshi
Kumada Hiromitsu
Kamatani Naoyuki
Nakamura Yusuke
収録物名
Gastroenterology
136
5
開始ページ 1796
終了ページ 1805
抄録
Background & Aims: This study aimed to identify host single nucleotide polymorphisms (SNPs) that are associated with the efficacy of interferon (IFN) therapy in patients with chronic hepatitis C. Methods: We examined whether 116 tagging-SNPs from 13 genes that are involved in type I IFN signaling associate with the outcome of IFN therapy in Japanese case-control groups; the study included 468 sustained responders and 587 nonresponders. Results: We identified 2 SNPs (rs3792323 [A/T] and rs616589 [G/A]), located in intron 2 of mitogen-activated protein kinase-activated protein kinase 3 (MAPKAIPK3) that were associated with the outcome of IFN therapy in patients infected with hepatitis C virus (HCV) genotype 1b (P = 4.6 X 10(-5) and 4.8 X 10(-5), respectively). The 2 SNPs were in strong linkage disequilibrium and multivariate logistic regression analysis showed that rs3792323 is an independent factor associated with the IFN efficacy (genotype 1b; P =.0011). MAPKAPK3 is a kinase involved in the mitogen and stress responses, but the biological significance of MAPKAPK3 in IFN responses is poorly understood. By using an allele-specific transcript quantification assay in liver biopsy, we showed that allelespecific expression of MAPKAPK3 messenger RNA, corresponding to the risk allele for nonresponse, was significantly higher than that of the other allele. Luciferase reporter assay data indicated that overexpression of MAPKAPK3 inhibits IFN-alfa-induced gene transcription via IFN-stimulated response element and IFN gamma-activated site. Conclusions: The SNP rs3792323 in MAPKAPK3 associates with the outcome of IFN therapy in patients with HCV genotype 1b. Our functional analyses indicate that MAPKAPK3 inhibits IFN-alfa-induced antiviral activity.
言語
英語
資源タイプ 学術雑誌論文
出版者
W B Saunders Co-Elesvier Inc
発行日 2009
権利情報
Copyright (c) 2009 AGA Institute Published by Elsevier Inc.
出版タイプ Author’s Original(十分な品質であるとして、著者から正式な査読に提出される版)
アクセス権 オープンアクセス
収録物識別子
[ISSN] 0016-5085
[DOI] 10.1053/j.gastro.2009.01.061
[NCID] AA0065394X
[DOI] http://dx.doi.org/10.1053/j.gastro.2009.01.061